West Pharmaceutical Services (WST) Cash from Financing Activities (2009 - 2026)
West Pharmaceutical Services (WST) posted Cash from Financing Activities of -$164.8 million for Q2 2026, up 46.61% sequentially from -$308.7 million in Q1 2026, and down 1006.04% YoY from $18.2 million in Q2 2025.
West Pharmaceutical Services (WST) Cash from Financing Activities (2009 - 2026) Analysis & Trends
West Pharmaceutical Services has reported Cash from Financing Activities for 18 years, with the latest figure at -$164.8 million in Q2 2026.
- Quarterly Cash from Financing Activities fell 1006.04% year-over-year to -$164.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$496.7 million (down 68.26% YoY) and the FY2025 annual result came in at -$185.1 million, up 70.27% from the prior year.
- Cash from Financing Activities rose to -$164.8 million in Q2 2026 per WST's latest filing, from -$308.7 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at -$9.5 million in Q4 2022 and troughed at -$308.7 million in Q1 2026.
- A 5-year average of -$113.0 million and a median of -$73.1 million in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 12166.67% in 2022, then surged 93.17% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$9.5 million in 2022, then slumped by 1894.74% to -$189.5 million in 2023, then jumped by 63.64% to -$68.9 million in 2024, then soared by 83.02% to -$11.7 million in 2025, then tumbled by 1308.55% to -$164.8 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$164.8 million, -$308.7 million, and -$11.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Align Technology | 11.61 Bn | 10.51 Bn | 757.43 Mn | -67.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -164.80 Mn |
| Jun 30, 2026 | -164.80 Mn |
| Mar 31, 2026 | -308.70 Mn |
| Mar 31, 2026 | -308.70 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Sep 30, 2025 | -11.50 Mn |
| Sep 30, 2025 | -11.50 Mn |
| Jun 30, 2025 | -14.90 Mn |
| Jun 30, 2025 | -14.90 Mn |
| Mar 31, 2025 | -147.00 Mn |
| Mar 31, 2025 | -147.00 Mn |
| Dec 31, 2024 | -68.90 Mn |
| Dec 31, 2024 | -68.90 Mn |
| Sep 30, 2024 | -64.40 Mn |
| Sep 30, 2024 | -64.40 Mn |
| Jun 30, 2024 | -218.30 Mn |
| Jun 30, 2024 | -218.30 Mn |
| Mar 31, 2024 | -271.00 Mn |
| Mar 31, 2024 | -271.00 Mn |